20200107 PR TG4050 FPI – EN
Category: Press release
Transgene Announces Financial Calendar for 2020
20191218 Financial calendar 2020 EN
Transgene Reports on the Combination Trial of TG4010, Chemotherapy and Nivolumab in Non-Small Cell Lung Cancer
20191212 PR TG4010_EN_results
Transgene and BioInvent announce compelling preclinical data for BT-001 in solid tumors
20191211 PR preclinical BT001 EN
Transgene Announces Investor Meetings for January 2020
20191209 PR Investors Meeting agenda 2020
Transgene Provides Q3 2019 Business Update, with Focus on Recently Announced Efficacy Results of TG4001
20191114 Résultats T3-2019 EN
Transgene Will Participate in the Jefferies 2019 London Healthcare Conference
20191022 – Transgene PR Jefferies EN
Transgene Reports First Promising Efficacy Results with TG4001 in Combination with Avelumab in HPV-Positive Cancer at ESMO 2019
20190930 PR TG4001 ESMO EN
Transgene Confirms the Timeline of its Clinical News Flow and Presents 2019 Half-Year Results
20190918-Transgene-H1-2019-RESULTS-EN
Transgene Receives Approval from the French Health Authority (ANSM) to Initiate Two Clinical Trials of its Lead myvac® Individualized Immunotherapy TG4050
20190916 PR ANSM TG4050 EN